---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-003649"
form_type: "8-K"
ticker: "PULM"
cik: "0001574235"
company_name: "Pulmatrix, Inc."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:04:00.577509+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Pulmatrix doses first patient in Phase 2b trial of PUR1900 for ABPA with asthma

## Summary
- First patient dosed in randomized, double-blind, placebo-controlled Phase 2b study of inhaled itraconazole (PUR1900) for ABPA in asthma.
- Study targets 30 subjects across US, UK, Australia, France; 3 arms: placebo, 20 mg, 40 mg daily for 16 weeks plus 8-week follow-up.
- Partnership with Cipla; proof-of-concept data expected by mid-2024.
- PUR1900 aims to be first approved ABPA treatment, reducing systemic side effects of oral antifungals.

## SEC filing metadata
- accession: 0001493152-23-003649
- form_type: 8-K
- ticker: PULM
- cik: 0001574235
- company_name: Pulmatrix, Inc.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1574235/000149315223003649/0001493152-23-003649-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1574235/000149315223003649/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-003649
- JSON: https://secwatch.observer/filing/0001493152-23-003649.json
- Plain text: https://secwatch.observer/filing/0001493152-23-003649.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.